Liu Yu, Wang Ping, Shi Xiuqun, Li Huijin, Zhang Xionghui, Zeng Shenghu, Xu Zhoufa, Lai Dongqing, Zhang Minling
Department of Orthopaedics, Heyuan Hospital of Chinese Medicine.
Department of Critical Care Medicine, Beijing University of Chinese Medicine Shenzhen Hospital.
Medicine (Baltimore). 2019 Apr;98(16):e15282. doi: 10.1097/MD.0000000000015282.
Primary osteoporosis (POP) is one kind of global disease, as a serious threat to human health. Liuwei Dihuang Decoction (LWDHD) has been recommended to treat osteoporosis alone or combined with medicine in China; however, its efficacy is unclear. The object of this systematic review and meta-analysis is to evaluate the efficacy and safety of LWDHD in the management of POP.
We will search The Cochrane Library, Medline, PubMed, Elsevier, Springer, Web of Science, Ovid, WHO ICTRP, CNKI, CBM, VIP, and WanFang Database from their inception to February 2019. All randomized controlled trials (RCTs) of LWDHD for the treatment of POP will be included. The language is limited to Chinese and English. The fracture incidence will be accepted as the primary outcomes. Data synthesis, subgroup analysis, sensitivity analysis will be performed by using RevMan V.5.3.5 software.
A high-quality synthesis of current evidence for the treatment of POP with LWDHD will be provided from efficacy and safety.
This systematic review will generate evidence for judging whether LWDHD is an effective and safe intervention for POP or not.
PROSPERO CRD 4201926066.
原发性骨质疏松症（POP）是一种全球性疾病，严重威胁人类健康。在中国，六味地黄丸（LWDHD）已被推荐单独或与药物联合用于治疗骨质疏松症；然而，其疗效尚不清楚。本系统评价和荟萃分析的目的是评估六味地黄丸治疗原发性骨质疏松症的疗效和安全性。
我们将检索Cochrane图书馆、Medline、PubMed、Elsevier、Springer、Web of Science、Ovid、WHO国际临床试验注册平台、中国知网、中国生物医学文献数据库、维普资讯和万方数据库，检索时间从建库至2019年2月。纳入所有六味地黄丸治疗原发性骨质疏松症的随机对照试验（RCT）。语言限于中文和英文。骨折发生率将作为主要结局。使用RevMan V.5.3.5软件进行数据合成、亚组分析和敏感性分析。
将从疗效和安全性方面提供关于六味地黄丸治疗原发性骨质疏松症现有证据的高质量综合分析。
本系统评价将为判断六味地黄丸是否为治疗原发性骨质疏松症的有效和安全干预措施提供证据。
PROSPERO注册号：PROSPERO CRD 4201926066。
